GOA Therapeutics Corp — SEC Form D Filing

GOA Therapeutics Corp filed an SEC Form D on November 5, 2026, reporting $300K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
November 5, 2026
Amount reported
$300K
Round stage
Pre-seed, based on an initial $300,000 equity financing round to fund early preclinical development.
Industry
Pharmaceuticals
Website
https://goathera.com/**

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(c). Incorporated: DELAWARE

Problem

Acute alcohol intoxication and alcohol poisoning lack fast-acting targeted therapeutics, leaving healthcare providers reliant on passive supportive care to clear toxic blood alcohol levels.

Solution

GOA Therapeutics develops GOA26, an investigational drug candidate designed to rapidly lower blood alcohol concentration and sequester toxic acetaldehyde during acute poisoning events.

Why now

Increasing hospital emergency department admissions related to severe alcohol toxicity have created urgent demand for active pharmacological interventions that accelerate metabolic clearance.

Source: SEC EDGAR Form D filing